

An update to SPIRIT and CONSORT reporting guidelines to enhance transparency in randomised trials

Sally Hopewell¹, Isabelle Boutron^{2,3}, An-Wen Chan⁴, Gary S Collins⁵, Jennifer A de Beyer⁵, Asbjørn Hróbjartsson^{6,7}, Camilla Hansen Nejtgaard^{6,7}, Lasse Østengaard^{6,7}, Kenneth F Schulz⁸, Ruth Tunn¹, David Moher⁹

1. Oxford Clinical Trials Research Unit / Centre for Statistics in Medicine, University of Oxford, UK
2. Université Paris Cité, Inserm, INRAE, Centre de Recherche Epidemiologie et StatistiqueS, Université Paris Cité, F-75004 Paris, France
3. Centre d'Epidémiologie Clinique, AP-HP, Hôpital Hôtel Dieu, F-75004 Paris, France
4. Department of Medicine, Women's College Research Institute, University of Toronto, Canada
5. UK EQUATOR Centre / Centre for Statistics in Medicine, University of Oxford, UK
6. Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark, Department of Clinical Research, University of Southern Denmark, Denmark
7. Open Patient Data Explorative Network (OPEN), Odense University Hospital, Denmark
8. Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, USA
9. Centre for Journalology, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Canada

Corresponding Author: Professor Sally Hopewell, Oxford Clinical Trials Research Unit / Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Email: sally.hopewell@csm.ox.ac.uk

Results from clinical trials can only be deemed trustworthy if they are properly conducted and their methods are fully reported. The SPIRIT and CONSORT checklists, which have improved clinical trial design, conducting and reporting, are being updated to reflect recent advances and improve the assessment of healthcare interventions.

Well-designed and properly executed randomised trials provide the most reliable evidence on the benefits and harms of healthcare interventions. Ensuring transparent and complete reporting is essential in order to assess the reliability and reproducibility of randomised trials (1). Attention has been drawn to problems with the entire research process, from the research questions being asked and the methods used to conduct research, through to how studies are reported (2).

Informative critical appraisal of the quality of randomised trials is possible only if their design, conduct, and analysis are thoroughly and accurately reported. However, there is overwhelming evidence that the completeness of reporting of randomised trials is suboptimal (3), meaning that health care providers, patients, and the scientific community cannot reliably distinguish research that is more versus less trustworthy. The rapidly expanding number of COVID-19-related clinical trials has highlighted the urgent need for complete and timely reporting of study methods and results to inform patient care and public health policy. During the COVID-19 pandemic, a large living systematic review showed that 43% of 251 trials did not report information related to the randomisation process; half did not report complete information related to the beneficial effect; and 86% provided insufficient information on any harms (4).

Incomplete reporting

Trials with inadequate methods are associated with bias, especially exaggerated treatment effects. A study of 234 unique meta-analyses containing 1973 trials found that intervention effect estimates were exaggerated in trials with inadequate or unclear random-sequence generation, inadequate or unclear allocation concealment, and/or lack of or unclear blinding (5). Without a complete published description of the intervention, researchers are unable to replicate or build on research findings. This leaves clinicians, patients, and other decision makers unclear about how to reliably implement an effective intervention and apply the results of trials in clinical practice (6, 7).

Without clear reporting of trial methods and results, readers are unable to judge the reliability and validity of trial findings and extract information for systematic reviews. For example, a study showed that 41% of randomised trials included in systematic reviews were at unclear risk of bias in at least

one domain of assessment, mainly because of incomplete reporting (8). Trial protocols are also important because this pre-specifies the methods used in the trial, such as the primary outcome, thereby reducing the likelihood of undeclared post-hoc changes to the trial such as outcome switching. Prevalent practices, such as unclear reporting of methods and primary outcome switching, result in a distortion of the evidence-base (9).

Issues around poor reporting of research are arguably one of the aspects of research waste that is easiest to fix, as highlighted by Doug Altman in 1996, who pointed out that “readers should not have to infer what was probably done, they should be told explicitly” (10). Efforts to improve the reporting of randomised trials gathered impetus in the mid-1990s (Figure 1) and resulted in publication of the Standardized Reporting of Trials (SORT) Statement and Asilomar guidelines in 1994. These initiatives then led to publication of the CONSORT (CONsolidated Standards Of Reporting Trials) Statement in 1996 (11), which was revised in 2001 (12) and last updated in 2010 (13), along with an updated CONSORT Explanation and Elaboration article, with a strong pedagogical focus (14). Similar problems related to the lack of clear and transparent reporting of trial protocols led to the development of the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) Statement, published in 2013 (15), and its accompanying Explanation and Elaboration document (16) explaining and illustrating the principles underlying the Statement. SPIRIT and CONSORT are evidence-based guidelines, comprising a checklist of essential items that should be included in protocols and primary reports of completed randomised trials, respectively, and include a diagram documenting the flow of participants through a trial. The statements provide guidance to authors on the minimum information that should be included when reporting trials in order to ensure that trial protocols and trial reports are clear, complete, and transparent (13, 14).

Impact of SPIRIT and CONSORT guidelines

The main impact of SPIRIT and CONSORT guidelines is their endorsement by journals, which has improved clinical trial reporting. This endorsement informs prospective authors of the degree of transparency and completeness journals expect from authors in their trial protocols and reports of completed trials. In 2012 a Cochrane review of 50 evaluations of 16,604 trials assessed the effect of journals’ endorsement of CONSORT on the reporting of trials they publish. 25 out of 27 CONSORT-related checklist items measured were more completely reported when the trial was published in an endorsing journal, compared with trials published in non-endorsing journals (3).

CONSORT has been heavily cited (17), is listed among the top health research milestones of the 20th century according to the Patient-Centered Outcomes Research Institute (18), and is among the top 1% of all research articles by article-level metrics, as tracked by Scopus (13, 19). CONSORT 2010 has been translated into 13 languages and SPIRIT 2013 into 7 languages. CONSORT and SPIRIT have received global endorsement by prominent editorial organisations, including the World Association of Medical Editors (WAME), International Committee of Medical Journal Editors (ICMJE), and Council of Science Editors (CSE), and organisations such as the European Clinical Research Infrastructure Network and the pharmaceutical industry.

Updating the guidelines

SPIRIT and CONSORT have evolved over time (Figure 1) and have been developed and led separately, leading to misalignment between the two. The SPIRIT and CONSORT Executive Groups have recently merged to form one Group, with a common strategy for updates and extensions. The SPIRIT–CONSORT Executive Group is planning a major joint update of the SPIRIT 2013 and CONSORT 2010 Statements and accompanying Explanation and Elaboration documents concurrently. It is more than 10 years since the CONSORT Statement was last updated and 9 years since SPIRIT was published. It is vital that the guidelines are periodically updated to reflect methodological advancements and feedback from users, otherwise their value and usefulness will diminish over time, rendering them no longer fit for purpose. In the era of increased transparency of clinical research and new evidence, it is more important than ever that SPIRIT and CONSORT remain current and relevant to end users.

The aim of updating the SPIRIT 2013 and CONSORT 2010 Statements together is to align reporting in both checklists and to provide users with consistent guidance in the reporting of trial design, conduct, and analysis, from trial protocol to final publication. Streamlining and harmonising the reporting process will improve usability and adherence, leading to more complete reporting. SPIRIT and CONSORT have some overlap, particularly for methodological items related to trial design, and further alignment will facilitate usability and implementation, as well as being more efficient.

Several existing and emerging initiatives need to be considered during the update. For example, the TIDieR (Template for Intervention Description and Replication) Statement has argued for improvements to the completeness of reporting, and ultimately the replicability, of trial interventions (6). The involvement of patients and the public in the design and conduct of health and social care research is now widely recognised as essential and so this involvement should be clearly reported in the trial protocol and in the trial results (20). Data sharing of clinical trial results is evolving quickly and

will be addressed in the updates; authors need to be aware of this changing landscape. Funders are starting to require explicit data management plans and data sharing requirements in grant applications in addition to statistical analysis plans (SAPS) (21). Journals are also starting to require trial results data sharing (i.e., individual de-identified participant-level trial data) prior to publication. As with previous updates of CONSORT, existing SPIRIT and CONSORT checklist items will be examined to revisit their wording and ensure their continuing completeness and scientific accuracy. For example, the CONSORT 2010 update added a new item that asked authors to specify how blinding was done. The item asking authors to explain how the success of blinding was assessed was deleted as part of the CONSORT 2010 update (14) because of a lack of evidence supporting this practice.

SPIRIT is aimed at protocols of randomised trials while CONSORT is aimed at primary reports of completed randomised trials with two-group parallel designs. A number of core extensions to SPIRIT and CONSORT have been developed to tackle the methodological issues associated with reporting different types of trial designs, data, and interventions (Table 1). Additionally, applications of SPIRIT and CONSORT have been developed to interpret standard guidance in specific contexts, such as trials in specific disease areas or populations. However, the growing number of extensions is making their use and application increasingly burdensome for end users, reducing the value of these tools. As part of updating SPIRIT and CONSORT, certain key extensions whose checklist items apply to all trials will be incorporated into the main SPIRIT and CONSORT checklists. This includes the CONSORT extension for reporting of harms-related data in randomised trials (22), which is currently being updated, and a new SPIRIT and CONSORT extension for reporting of outcomes in trial protocols and trial reports (23). By incorporating checklist items from key extensions, a more comprehensive trial protocol and primary report will be established (24).

One of the challenges for the SPIRIT–CONSORT Group is how to better facilitate dissemination, endorsement, and implementation to improve adherence to these guidelines and their extensions. The SPIRIT (www.spirit-statement.org) and CONSORT (www.consort.statement.org) websites encompass various initiatives aimed at improving the reporting of randomised trials. In 2020, more than 200,000 unique users visited the CONSORT website and 73,000 visited the SPIRIT website. Funding has been secured to create a new joint SPIRIT–CONSORT website, with new resources aimed at researchers, journal editors, and peer reviewers, explaining the main changes to the SPIRIT and CONSORT checklist guidance and how the updated guidance should be used.

The EQUATOR Network has established methods for developing health research reporting guidelines; these will be used to update SPIRIT 2013 and CONSORT 2010 (25), following similar methodology used to develop recent CONSORT and SPIRIT extensions. The update will happen in five stages, outlined in Table 2. A wide range of stakeholders with broad geographical representation will be included in the update process, in order to ensure implementation and adherence of the new guidelines. Stakeholders will include clinical trial researchers and clinicians, as well as representatives from funding bodies, ethics committees, medical journals, regulatory agencies, and industry. The views of patients and the public are also essential, as the research would not be possible without them, and they are directly affected by the results of clinical trials. Stakeholders interested in this project, and who wish to take part in the Delphi survey process, should register their interest via the SPIRIT–CONSORT project website [\[TO INSERT LINK TO EOI FORM\]](#).

SPIRIT–CONSORT Working Group: Prof Sally Hopewell (University of Oxford), Prof Isabelle Boutron (Université Paris Cité), Prof An-Wen Chan (University of Toronto), Prof Gary S Collins (University of Oxford), Dr Jennifer A de Beyer (University of Oxford), Prof Asbjørn Hróbjartsson (University of Southern Denmark), Dr Camilla Hansen Nejstgaard (University of Southern Denmark), Lasse Østengaard (University of Southern Denmark), Prof Kenneth F Schulz (University of North Carolina at Chapel Hill), Dr Ruth Tunn (University of Oxford), Prof David Moher (Ottawa Hospital Research Institute, University of Ottawa).

Acknowledgements: The author(s) disclose receipt of the following financial support for the research, authorship and/or publication of this article: This work is supported by the Medical Research Council – National Institute for Health Research Better Methods, Better Research [MR/W020483/1] (SH, RT, JdB, GSC). The funder is not involved in any aspect of the research work. JdB and GSC are supported by Cancer Research UK (C49297/A29084). GSC is supported by the NIHR Biomedical Research Centre, Oxford. This reporting guideline under development is registered on the Enhancing Quality and Transparency of Health Research (EQUATOR) Network database. Approval for the Delphi survey was obtained from the Central University Research Ethics Committee (CUREC), University of Oxford [20 July 2022; R76421/RE001].

Author contributions: IB, AC, SH, AH, DM and KFS were responsible for the concept, SH, IB, AC, GC, AH, DM and KFS were responsible for the funding. SH and IB drafted the manuscript; all authors critically revised the manuscript for important intellectual content and approved the final version.

Competing interests: The authors are all involved in the development, update, implementation, and dissemination of numerous reporting guidelines. IB, AC, SH, AH, DM and KFS are members of the SPIRIT-CONSORT Executive Group. GSC is the Director of the UK EQUATOR Centre, DM is the Director of the Canadian EQUATOR Centre, and JdB is affiliated with the UK EQUATOR Centre, which are all part of the EQUATOR Network, an organisation that promotes reporting guidelines. IB is deputy director of the French EQUATOR Centre.

Figure legends

Figure 1: Timeline for the development of the SPIRIT and CONSORT Statements




Table 1: Extensions to SPIRIT and CONSORT

Statement	Type	Extension
SPIRIT www.spirit-statement.org	Design	Early phase dose finding trials*
		Factorial trials
		N-of-1 trials
		Pilot and feasibility trials*
	Data	Patient reported outcomes
		Outcomes*
		Pathology*
CONSORT www.consort-statement.org/extensions	Design	Adaptive designs
		Cluster trials
		Crossover trials
		Early phase dose finding trials*
		Factorial trials*
		Multicentre trials
		Non-inferiority and equivalence trials
		N-of-1 trials
		Pilot and feasibility trials
		Pragmatic trials
		Stepped wedge cluster trials
		Trials using cohort and routinely collected data*
		Within person trials
	Data	Abstracts
		Equity
		Harms**
		Outcomes*
		Patient reported outcomes
	Interventions	Non-pharmacologic treatments

*Extension guideline in development; **Extension guideline being updated

Table 2. Process for updating SPIRIT 2013 and CONSORT 2010

Step	Process
1. Literature review	Conduct scoping review of comments on SPIRIT and CONSORT including suggestions for modifications Develop database of the literature to identify new evidence relevant to reporting of randomised trials
2. Delphi survey	Conduct international Delphi survey to obtain views of a diverse range of stakeholders on potential changes and modifications to SPIRIT and CONSORT checklists
3. Consensus meeting	Establish consensus among a broad range of stakeholders on items to include in the updated SPIRIT and CONSORT checklists
4. Checklist and E&E revision	Revise and update the SPIRIT and CONSORT checklists and accompanying Explanation and Elaboration (E&E) documents Pilot the revised checklists
5. Dissemination and implementation	Create dissemination materials and run campaigns targeting those who can reach authors, such as journals, language professionals, and educators Create a new joint SPIRIT–CONSORT website, online training modules, and new patient-facing portal

References

1. Goodman, S. N., Fanelli, D. & Ioannidis, J. P. *Sci. Transl. Med.* **8**(341), 341ps12 (2016).
2. Ioannidis, J. P. et al. *Lancet* **383**(9912), 166–175 (2014).
3. Turner, L. et al. *Syst. Rev.* **1**, 60 (2012).
4. Kapp, P. et al. Preprint at <https://www.medrxiv.org/content/10.1101/2022.02.03.22270357v1> (2022).
5. Savovic, J. et al. *Ann. Intern. Med.* **157**(6), 429–438 (2012).
6. Hoffmann, T. C. et al. *BMJ* **348**, g1687 (2014).
7. Glasziou, P. et al. *Lancet* **383**(9913), 267–276 (2014).
8. Yordanov, Y. et al. *BMJ* **350**, h809 (2015).
9. Goldacre, B. et al. <https://www.compare-trials.org/> (2016) (accessed 26 May 2021).
10. Altman, D. G. *BMJ* **313**(7057), 570–571 (1996).
11. Begg, C. et al. *JAMA* **276**(8), 637–639 (1996).
12. Moher, D., Schulz, K. F. & Altman, D. *JAMA* **285**(15), 1987–1991 (2001).
13. Schulz, K. F., Altman, D. G. & Moher, D. *BMJ* **340**, c332 (2010).
14. Moher, D. et al. *BMJ* **340**, c869 (2010).
15. Chan, A. W. et al. *Ann. Intern. Med.* **158**(3), 200–207 (2013).
16. Chan, A. W. et al. *BMJ* **346**, e7586 (2013).
17. Caulley, L. et al. *J. Clin. Epidemiol.* **127**, 96–104 (2020).
18. Gabriel, S. E. & Normand, S. L. N. *Engl. J. Med.* **367**(9), 787–790 (2012).
19. SCOPUS. <https://www.scopus.com> (accessed 28 July 2022).
20. Staniszewska, S. et al. *Int. J. Technol. Assess. Health Care* **27**(4), 391–399 (2011).
21. Gamble, C. et al. *JAMA* **318**(23), 2337–2343 (2017).
22. Ioannidis, J. P. et al. *Ann. Int. Med.* **141**(10), 781–788 (2004).
23. Butcher, N. J. et al. *Trials* **21**(1), 620 (2020).
24. Ghosn, L., Boutron, I. & Ravaud, P. *J. Clin. Epidemiol.* **113**, 168–175 (2019).
25. Moher, D. et al. *PLoS Med.* **7**(2), e1000217 (2010).